A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants
Latest Information Update: 26 Jun 2023
At a glance
- Drugs V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms V114-033
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 19 Jun 2023 Results published in the Vaccine
- 04 Jan 2022 New source identified and integrated (European Clinical Trials Database: EudraCT2019-003644-68).
- 04 Jan 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI205287)